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" Our patients have the right to demand that their endocrine surgical problems 
are handled by specialists with deep knowledge not only on technical aspects but 
also of physiology and pathology of endocrine diseases... "  
(Langenbecks Arch Surg 2008; 393:619) 
 
" The rapid transformation of new experimental data to diagnosis and treatment 
of patients will further increase the demand of the surgeon to be updated on 
medical progress to avoid a future role as surgical technician, soon to be 
replaced by a robot. "  
(Arch Surg 1998; 133:326) 
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ABSTRACT 
An adrenocortical tumour (ACT) can be detected in up to 5% of the population older than 50 
years of age. The frequency increases with age. More ACTs are being detected in parallel with 
the increased use of high-resolution imaging. When there is clinical or biochemical evidence of 
excess hormonal secretion from an ACT, a careful and systematic clinical evaluation is 
compulsory. An abnormally elevated secretion of a particular steroid such as aldosterone, 
cortisol or dehydroepiandrosterone is frequently associated with a benign phenotype, 
adrenocortical adenoma (ACA). Adrenocortical carcinoma (ACC) is a rare tumour with a 
relatively poor prognosis; 5-year overall survival is about 30-35%. Approximately half of 
ACCs are hyperfunctioning, and therefore ACC diagnosis is more often based on its imaging 
phenotype or by histological characteristics (Weiss Score) rather than the hormonal profile. 
Suspicion of malignancy or proven hormone production with clinical significance in ACTs 
should lead to prompt surgical resection. The overall aim of this thesis was to explore by means 
of transcriptomic profiling the differences between ACT regarding the malignant and 
hyperfunctioning phenotypes. 
 
Paper I shows the main divergences between ACC and benign ACT at the transcriptomic level. 
Several genes were up regulated in ACC, including genes related to the IGF family. 
Transcriptional profiling through the use of cDNA arrays allows discrimination between ACC 
and ACA. 
 
Paper II emphasizes the use of mRNA transcriptomics for distinguishing the hyperfunctioning 
phenotypes and prognosis in ACA and ACC respectively. Some specific mRNAs are closely 
related to certain functional phenotypes, for example aldosterone-producing adenoma (APA) 
with OSBP and VEGFB. Additionally, two subgroups of ACC with different survival times 
were distinguished based on their transcriptomic mRNA profiles. 
 
Paper III demonstrates that the transcriptomic profile based on microRNA (miRNA) 
expression is also useful for discriminating ACA from ACC. Moreover, certain miRNAs were 
significantly associated with survival time among ACC patients. The functional role of some 
stochastic miRNAs determined in ACC was additionally investigated. Transcriptomic profiling 
of miRNAs is not limited exclusively to classification but also for predicting clinical outcome 
in ACC. 
 
Paper IV also explores miRNA-based transcriptomics for classifying the most common ACA 
phenotypes: cortisol-producing adenoma (CPA), APA and non-hyperfunctioning adenoma 
(NHFA). CPA and APA clustered separately from each other, when NHFA were excluded. 
Moreover, NHFA were spread out in these two clusters. Certain miRNAs were specific mainly 
among hyperfunctioning ACA. Specific miRNAs associated with different tumour phenotypes. 
 
Keywords: Adrenocortical tumours, adrenocortical adenoma, adrenocortical carcinoma, RNA 
expression, microRNA, non-hyperfunctioning, cortisol-producing adenoma, aldosterone-
producing adenoma, tumour phenotype. 
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1 INTRODUCTION 
 
Bartholomeus Eustachius was the first to describe the adrenal glands in 1552. He 
described the location of these glands above both kidneys named them as "glandulae 
renis incumbentes" in his Opuscula Anatomica. Although they were described since 
the XIV century, many prominent physicians later on including André Vesalius failed 
to confirm this finding. Moreover, their function remained unknown for centuries until 
1855, when Thomas Addison described for the very first time the clinical picture of 11 
patients with destruction of the adrenal glands, now defined with his eponymous 
clinical syndrome1.   
 
In 1805, Georges Léopold Chrétien Cuvier describe for the very first time that the 
adrenal glands were composed of a peripheral cortex and central medulla. 
Unfortunately, Cuvier was not able to infer any functional role for these parts. Cuvier 
was a French naturalist with a large number of contributions, which in turn was 
immortalized by Gustav Eiffel by the inscription of his name among 72 other 
prominent French scientists, engineers and mathematicians on the sides of the tower 
under the fist balcony on the Eiffel Tower. 
 
In 1856, Charles-Édouard Brown-Séquard, the one of the first to postulate the 
existence of substances now known as hormones, demonstrated that the removal of the 
adrenal glands resulted in death due to the lack of their essential hormones. Although 
he was very criticized and caused controversy at those times for his experimental 
works, he is nowadays considered the father of the modern endocrinology. He was one 
of the first to advocate the use of hormonal preparations obtained from tissue extracts 
for prolonging human life2. 
 
1.1 The adrenal cortex  
 
The adrenal glands form a paired and triangle-shaped endocrine organ localized at the 
top of the kidneys (Figure 1). In human adults, the normal weight is 4-6 g and the 
greatest diameter 4-5 cm3-5. The adrenal gland is an extraordinary conjunction of two 
endocrine tissue types with different embryonic origin and functional properties6-10. 
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The adrenal medulla originates from the neural crest and produces bioactive amines 
whereas the adrenal cortex arises from mesenchymal cells attached to the coelomic 
cavity epithelium and produces steroid-derived hormones8-15.  
 
 
Figure 1. Macroscopic appearance of the adrenal glands. The cut surface 
shows a yellowish outer layer known as the cortex, and an inner layer termed 
the medulla. 
 
Autonomic nerves directly stimulate the adrenal medulla and therefore the response is 
immediate with catecholamine secretion. In contrast, the adrenal cortex is stimulated 
by the adrenocorticotropic hormone (ACTH), secreted from the anterior pituitary, 
which in turn is also stimulated by the hypothalamus. ACTH induces synthesis and 
secretion of adrenal steroids in a circadian mode. In general terms, adrenocortical 
steroids modulate the glycaemia and electrolyte levels, mainly sodium. Compared to 
the rapid response of the medulla, the cortex may exert its secretion and hormonal 
action for longer periods of time. During foetal development until one year 
postpartum, two zones are evident in the adrenal glands: an inner prominent zone and 
an outer zone that further differentiates into the adult definitive adrenal gland4, 10, 14. 
After birth, the outer zone develops two zones; an internal one, which further 
differentiates into the zona fasciculata and an external that becomes the zona 
glomerulosa. Additionally, some growth factors such as IGF-II have been implicated 
in this functional development of the foetal adrenal cortex16-22. 
 
The adrenal cortex surrounds the medulla and constitutes a major proportion (85-90%) 
of the entire gland. From a functional and anatomical point of view, the adrenal cortex 
includes three different layers that are from the external (beneath the capsule) to the 
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most internal stratum the following: zona glomerulosa, zona fasciculata and zona 
reticularis (Figure 2). 
 
Figure 2. Microscopic features of the different anatomical and functional zones 
within the adrenal cortex.  The zona fasciculata with its columnar disposition is 
the most abundant within the adrenal cortex.  A small fraction of adrenal medulla 
can be seen at the centre of the image. 
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Traditionally it has been established that the intermediate layer (zona fasciculata) is 
the widest zone comprising 75% of the cortex and mainly produces glucocorticoids. 
This layer includes large and lipid-laden cells forming radial cords between the 
fibrovascular radial networks. Mineralocorticoids such as aldosterone are mainly 
produced in the outer layer (zona glomerulosa), while sex or gonadal steroids are 
produced in the innermost layer (zona reticularis) 23-25 (Figure 3). Although this 
conventional zonation has been recently questioned26-30, it has long been useful for 
educative purposes.  
 
However, a more complex interaction within these layers with a differential growth 
has been advocated by some authors especially across the period of adrenarche24, 31-35. 
The adrenarche is an endocrine developmental process occurring in humans and other 
non-human primates that increase cortical sex steroids such as dehydroepiandrosterone 
(DHEA). This phenomenon corresponds with the expansion of the zona reticularis of 
the adrenal cortex around 6 years of age32. The phenotypic hallmark of this adrenarche 
is the appearance of axillary and pubic hair, enabling the future transformation of some 
other steroids to active forms of sex steroids such as testosterone further until the 
puberty. 
 
Steroidogenesis is a genetically guided complex biochemical and cellular process5, 12, 
36, 37 that ends up in the synthesis of steroid hormones (Figure 4)37-39. These hormones 
may be classified into three main types: glucocorticoids (for example cortisol and 
corticosterone); mineralocorticoids (aldosterone and deoxycorticosterone), and 
sex/gonadal steroids (such as oestrogen, testosterone and DHEA)4, 23. Glucocorticoids 
are secreted in relatively high amounts under the control of the ACTH while 
mineralocorticoids are secreted in lower amounts. For example while approximately 
10 milligrams of cortisol are usually secreted per day, only 100 micrograms of 
aldosterone are secreted in the same period of time. In contrast, adrenal androgens are 
the most abundant steroids secreted. More than 20 milligrams of DHEA are secreted 
each day from an adult adrenal cortex. 
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Cholesterol is the major substrate for this steroidogenesis within the adrenal cortex, 
which may be acquired from outer or inner sources into the circulation40, 41. Thereby, 
most steroid hormones share closely related molecular structures.  Although 
cholesterol is the precursor of all adrenal steroids, its main source is low-density 
lipoproteins (LDL). These LDL can be obtained from endogenous or exogenous 
sources. LDL uptake is performed by specific cell surface LDL receptors located on 
adrenal cortex cells. Once LDL is internalized via receptor mediated endocytosis, the 
resulting vesicles fuse with lysozymes and free cholesterol is then produced through 
hydrolysis. Once cholesterol is transported into the mitochondria, a set of 
enzymes/proteins (mainly cytochrome P450 enzymes) participate into the further 
metabolic changes to obtain a specific type of steroid hormone36, 37, 41-46.  
 
Steroidogenic genes mainly coordinate this process, in which ACTH plays a crucial 
role by exerting transcriptional pressure on these genes to synthesize adrenocortical 
steroids12, 36, 47 as well as the foetal adrenal development during pregnancy16, 17, 48, 49. 
Interestingly, small quantitative differences of these hormones may retain a human 
individual alive or paradoxically may cause an overt clinical syndrome.  
 
Steroidogenesis is a complex series of biochemical transformations beginning with 
cholesterol that has a basic core composed of a cyclo-perhydro-pentano-phenanthrene 
structure4, 37, 50. All the different cortical steroids such as oestrogens, androgens, 
mineralocorticoids and glucocorticoids share this biochemical core. The three major 
steps of steroidogenesis (Figure 4) from cholesterol uptake to functionally active 
steroids are: 
1.  Cholesterol uptake and intracellular transportation 
2.  Mitochondrial inclusion of cholesterol 
3.  Enzymatic processes 
a) Cytochrome P450 family (oxidative enzymes) 
i.  Type 1 or mitochondrial 
ii.  Type 2 in endoplasmatic reticulum 
b) Hydroxysteroid dehydrogenase family 
i. Aldo-keto reductases family 
ii. Short-chain dehydrogenase/reductase family 
  7 
 
Today, human diseases are known to be associated with all these steps. For example, 
in Wollman disease, adrenal insufficiency is induced due to unavailability of free 
cholesterol, and 21-hydroxylase deficiency is the most common cause of congenital 
adrenal hyperplasia37. The Cytochrome P450 family comprise enzymes composed with 
approximately 50 amino acids with a single heme group. The name reflects the fact 
that these enzymes are pigments and can absorb light at 450 nm in their reduced states. 
The genes and protein products in this family are also referred as CYP4, 37. The first 
conversion of cholesterol into pregnenolone is produced by P450, which is abundant in 
the three zones of the adrenal cortex (glomerulosa, fasciculata and reticularis). The 
participation of the other two families of enzymes determines the type of steroid to be 
produced and therefore its functional role. These steroidogenic enzymes also show a 
”zone-specific” distribution across the adrenal cortex3. For example, the zona 
glomerulosa is not able to synthesize cortisol because it does not contain a 17-alpha 
hydroxylase, whereas this zone is able to synthesize aldosterone because it produces 
CYP11B2.  On the first hand, classical endocrine feedback loops are in place to control 
the secretion of these hormones such as the corticotrophin-releasing factor 
(synthesized by the hypothalamus) and the ACTH (synthesized by the anterior 
pituitary). In addition, other stimuli may induce the synthesis of these hormones such 
as hyperkalaemia does for aldosterone secretion3, 5. 
 
On the other hand, a considerable amount of this enzymatic activity is regulated 
genetically and by posttranslational modifications. Moreover, discrete differences in 
the genetic sequences differ among this family (cluster) of steroidogenic genes. For 
example, CYP11B1 and CYP11B2 share approximately a 95% of homology, the 5 
prime promoter sequences of these genes differ. This allows the specific regulation by 
ACTH and Angiotensin II in the final steps of glucocorticoid and mineralocorticoid 
biosynthesis, respectively. Rare mutations are known in the corresponding genes, and 
the identification of these mutations has contributed to a better understanding of the 
genetic basis of adrenocortical tumours (ACT)37, 46, 51, 52. 
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Figure 4. Schematic diagram of the human steroidogenesis (obtained from 
http://www.vivo.colostate.edu/hbooks/pathphys/endocrine/basics/steroidogenesis.ht
ml). 
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1.2 Epidemiology of adrenocortical adenomas (ACA) and carcinomas (ACC) 
 
Adrenal tumours can be detected in up to 5% of the population older than 50 years of 
age53-57.  However, adrenocortical carcinoma  (ACC) is a rare malignancy, with a 
estimate incidence of 0.7-2 cases per million inhabitants per year based on data 
obtained from the National Cancer Institute58. ACC is also more frequent in women 
than in men with an estimated ratio of 1.5 times more. Although there have been a lot 
of speculation concerning the aetiology of ACC, this remains unclear for most of the 
cases. 
 
Today, more ACTs are being detected in parallel with the increased use of high-
resolution radiological imaging, especially computed tomography (CT) and magnetic 
resonance imaging (MRI)59. The general prevalence of ACT depends on the diagnostic 
method utilized and the patient's age. There is a correlation between age and the 
probability of neoplasia60, 61. The unsuspected discovery of an adrenal mass when a 
radiological examination is performed for reasons other than adrenal related symptoms 
is designated as adrenal incidentaloma53, 61-68. When there is clinical or biochemical 
evidence of hyperfunctioning hormonal secretion from these ACTs, a careful and 
systematic evaluation is compulsory56, 69-72.  
 
An abnormally elevated secretion of a particular steroid such as aldosterone, cortisol or 
DHEA is usually associated with benign growth properties. The proportion of 
adrenocortical adenomas (ACAs) among incidentalomas is high, while the malignant 
counterpart ACC is rare73, 74. An ACT with homogenous density, well delineated 
margins, without necrosis and a diameter not exceeding 4 cm are usually considered as 
ACA63, 70, 75-77.  
 
An ACA appear as a yellowish single nodule often with a microscopically well-
delineated transition between normal adrenal and adenoma (Figure 5). Nests with high 
mitotic rate and eosinophilic changes without invasion may also occur as well as 
nuclear pleomorphism or nuclear atypia.  
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In contrast, the macroscopic appearance of an ACC may include necrosis and a 
heterogeneous pattern (Figure 6). Typical microscopic features are a diffuse growth 
pattern with capsular invasion, surrounding tissue overgrowth, vascular invasion and 
necrosis with haemorrhagic foci. Some of these characteristics are considered in the 
Weiss score system, which is commonly used as a diagnostic and prognostic tool.  
 
 
Figure 5. Aldosterone-producing adenoma (APA). (A) Macroscopic 
appearance. Some microscopic features are showed in B and C such as a well-
delineated transition between normal adrenal and adenoma; a high mitotic rate 
in nests with eosinophilic changes without invasion can also occur (D).  
 
 
The prognosis of ACC is poor with a 5-year overall survival of about 30-35%54, 78, 79. 
Early detection is therefore important for ACCs and ACTs that may become 
malignant. A considerable proportion of ACCs are hyperfunctioning, and therefore 
ACC diagnosis is more based on its imaging phenotype than the hormonal or 
biochemical profiles. Any rational suspicion of malignancy or potential malignancy 
A B 
C D 
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should lead to surgical resection. Therefore, large ACTs, those that grow significantly 
between two separate imaging procedures, and those with radiological patterns 
indicating malignancy (irregularity, necrosis, diffuse margins, increased attenuation, 
etc) should be readily excised surgically. 
 
 
Figure 6. Adrenocortical carcinoma (ACC) Macroscopic appearance is shown 
in A and B. Microscopic features may include a diffuse growth pattern with 
capsular invasion (C), surrounding tissue overgrowth (D) vascular invasion (E) 
and necrosis with haemorrhagic foci (F).  
 
 
1.3 Clinical aspects of ACA and ACC 
 
In general terms, hormonally overactive ACTs are commonly benign. In ACA 
hormonal overproduction usually concerns one specific hormone normally produced 
by the adrenal cortex such as for example aldosterone or cortisol80, 81. However, many 
ACCs are also hyperfunctioning. Approximately half of ACCs produce steroids, 
causing clinical symptoms, often a mixture of several steroids and their derivatives, 
A B C 
D E F 
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reflecting de-differentiation of the tumour. Therefore, secretion profiling of steroids 
and their metabolites in urine may also serve as a tumour marker during screening, 
diagnosis and follow-up of ACTs55, 82-88. Androgen overproduction is usually restricted 
to the malignant phenotype of ACTs. 
 
A genetic predisposition to ACT may also be inherited in a Mendelian fashion (Figure 
7), which may be an important issue for genetic counselling in families with an 
increased risk. This is the case of a heterozygous mutation in the p53 gene located on 
chromosome 17p13.1, which causes the Li-Fraumeni syndrome. This syndrome is 
characterized by the early onset of multiple tumours such as sarcomas, osteosarcomas, 
breast cancer, brain tumours, brain tumours, leukaemia and ACC. This syndrome has 
an autosomal dominant pattern of inheritance affecting at least one first- or second 
relative in the same lineage at early age (before 45 years)89-91. 
 
Hypersecretion of aldosterone is known as primary aldosteronism (PA)92-94. This 
condition is the most frequent cause of endocrine hypertension95 and it is commonly 
associated with adrenocortical entities such as hyperplasia and a single aldosterone-
producing adenoma (APA)96, 97. The presence of a single APA is also referred in the 
literature to as Conn´s syndrome. Aldosterone is mainly synthesized in the zona 
glomerulosa induced by angiotensin II, hyperkalaemia or decreased intravascular 
volume. PA is clinically diagnosed based on resistant systemic arterial hypertension, 
hypokalaemia and abnormally high levels of plasma aldosterone when related to renin 
activity (high aldosterone:renin ratio) 98-100. These increased levels of aldosterone are 
produced by the adrenal cortex constitutively without any other secondary stimulus 
such as angiotensin II or hyperkalaemia. It is now recognized that many patients with 
PA do not present with hypokalaemia101, 102. Thereby, proper screening must include 
plasma aldosterone concentration (PAC), plasma renin concentration (PRC) and the 
PAC/PRC ratio. Normo-kalaemia must be obtained, and some antihypertensive drugs 
are not allowed during biochemical work-up. A much higher prevalence of PA has 
been determined with this approach when compared to the previous3.  
 
As many other endocrine diseases, PA is more properly diagnosed through the use of a 
three-phase clinical approach: 1) Detection tests (in suspected patients), 2) 
Confirmatory tests (of PA) and 3) Classification tests (of the different subtypes of PA).  
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Classification tests are used to identify subtypes of PA. These may include CT scan 
and adrenal venous sampling for distinguishing between APA and bilateral hyperplasia 
or glucocorticoid-remediable aldosteronism. These last two should be treated 
medically. Adrenal venous sampling for determining the dominating side for the 
aldosterone over-production is today golden standard94, 103-106. Ideally, the adrenal 
without over-production should be suppressed, but a PAC/PRC ratio exceeding three 
or four times, is usually considered as significant, and surgery should be offered to the 
patient107-111. Most commonly the CT scan reveals an adrenal mass, but these may be 
very small and escape detection (referred to as microadenomas). Furthermore, 
localisation studies apart from CT are mandatory, as an adrenal mass in a PA patient 
may be a non-hyperfunctioning incidentaloma. Aldosterone-producing carcinomas are 
extremely rare and exhibit an atypical clinical course112. 
 
Hypersecretion of cortisol may induce some clinical features characterized for a wide 
spectrum of conditions described as Cushing’s syndrome. This syndrome comprises 
many symptoms and signs associated with the prolonged exposure to inappropriately 
elevated levels of plasma glucocorticoids. These may include central obesity, facial 
plethora, moon facies, diabetes mellitus, arterial hypertension, gonadal dysfunction, 
hirsutism, bruising, red-purple striae, muscle weakness and osteoporosis among 
others3, 5. Etiological causes of Cushing`s syndrome may include exogenous iatrogenic 
administration, ACTH-dependent hypercortisolism and ACTH-independent which 
comprises the endogenous hypersecretion. Endogenous causes of Cushing`s syndrome 
are relatively rare and include a cortisol-producing adenoma (CPA).  CPA are 
responsible for about 10-15% of cases with Cushing`s syndrome. Cortisol-producing 
carcinomas are even less frequent. In contrast, in children 65% of these cases have an 
adrenal origin: 15% are CPA and 50% cortisol-producing ACC113-115. Hypersecretion 
of other steroids such as androgens or mineralocorticoids is also common among these 
tumours.  
  14 
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As aforementioned for PA, Cushing`s syndrome is also more properly diagnosed 
through the use of a three-phase clinical approach: 1) Detection tests (in suspected 
patients), 2) Confirmatory tests (of Cushing´s syndrome) and 3) Classification tests (of 
the different types/causes of Cushing´s syndrome). Detection tests may comprehend 
the presence of signs or symptoms that make the suspicion high for this syndrome such 
as hyperglycaemia, obesity and arterial hypertension.  
 
Confirmatory tests should comprise the measurement of 24-h plasma cortisol, 
secretion profiles, 24-hour urinary free cortisol excretion, and low-dose/overnight 
dexamethasone suppression tests.  These tests have displayed heterogeneous accuracy 
for the diagnosis of Cushing´s syndrome. This depends on the used assays and varies 
from institution to institution. For example, several authors have demonstrated that a 
midnight salivary cortisol ≥2 ng/mL has a greater diagnostic accuracy with a 100% 
sensitivity and 96% of specificity for the diagnosis of Cushing`s syndrome116-122.  
 
Once the biochemical confirmation has been done, it is necessary to investigate what is 
the cause and type of Cushing´s syndrome. For this purpose, classification tests are 
necessary. These may comprise midnight (23-01 hours) plasma ACTH (normal ≤20 
pg/ml), measurements of ACTH precursors (such as pro-ACTH and POMC), plasma 
potassium/mineralocorticoid secretion, high-dose dexamethasone suppression test, 
corticotropin-releasing factor test and imaging procedures. Clinical entities such as 
ectopic ACTH syndrome due to indolent carcinoid or subclinical Cushing may be 
discarded with these tests. 
 
Bilateral adrenocortical hyperplasia is present in approximately 10-40% of patients 
with Cushing´s syndrome114, 123. This pathologic condition is associated with one or 
more adrenocortical nodules with a great variety of diameters and morphology.   In 
some instances, this is associated to a chronic ACTH stimulation to the adrenal cortex. 
The more hyperplastic the adrenal glands become due to ACTH stimulation, the more 
the hypersecretion of cortisol is caused by adrenal hyperplasia. This overstimulation 
induces an “auto suppression” point, which may be confusing regarding this entity, as 
it may mimic an ACTH-independent form instead of the real ACTH-dependent origin 
that cause this irregular hyperplasia. A patient with CPA should have a low, if not 
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immeasurable, ACTH combined with an adrenal mass. Also in CPA patients, adrenal 
venous sampling may be mandatory. Bilateral disease, as in micronodular 
adrenocortical hyperplasia, is not always a contra-indication for surgery; venous 
sampling may allow removal of the dominant side, with sometimes a significant relief 
of symptoms from the cortisol over-production124-126. 
 
Finally, ACTs incidentally discovered by clinical imaging are commonly presenting as 
hormonally inactive masses or non-hyperfunctioning adenomas (NHFA)127. 
Hormonally active incidentalomas are reported to be diagnosed as CPA with or 
without Cushing’s syndrome in approximately 9-10%, as pheochromocytomas 
(catecholamine-producing tumours) in 4-5% and as APA in 1-2% of the cases 54. 
Approximately 60% of all diagnosed ACT but less than 10% of ACC are hormonally 
inactive41, 79. Unfortunately, a significant proportion of ACCs are initially diagnosed 
incidentally. Therefore, other features should also be taken in consideration for 
classification these tumours. For example, for tumours with a diameter less than 4 cm, 
there is a very low risk of malignancy, whereas this risk increases proportionally with 
an increasing diameter. Tumours larger than 6 cm are malignant in approximately 25% 
of the cases.60, 128 Histopathological criteria included in the Weiss score129, 130 are 
frequently used to assess the probability of malignancy in these tumours. These criteria 
include: 
 
1. High nuclear grade  
2. High mitotic rate (greater than 5/50 high power fields) 
3. Atypical mitoses 
4. Eosinophilic tumour cell cytoplasm (>75% of tumour cells) 
5. Presence of less than or equal to 25% of clear or vacuolated cells 
resembling the normal zona fasciculata 
6. Diffuse architectural pattern (greater than 33% of the tumour) with broad 
fibrous and trabecular bands. 
7. Foci of confluent necrosis 
8. Venous invasion 
9. Sinusoidal invasion 
10. Invasion of tumour capsule 
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When three or more of these criteria are found in an ACT, the phenotype is considered 
to be malignant129-132.  
 
While tumour diameter and radiological features can merely suggest malignancy, 
surgical excision is often necessary to obtain a definitive diagnosis in most cases. 
Moreover, diagnosis may be unclear in some cases, even after the histopathological 
analysis of the surgical specimen.  
 
Repeated radiological examinations may identify growing ACTs, and this usually 
leads to surgery, as malignant progression cannot be excluded. Taking the rarity of 
ACC into account, together with the non-negligible accumulated dose of radiation after 
repeated examinations, it is of importance to identify other measurable signs of 
malignant phenotypes in ACTs. Today the diagnostic and prognostic tools for 
distinguishing between benign and malignant ACTs are blunt. Therefore, a need for 
improved understanding of the molecular aetiologies of ACT, to develop 
complementary biomarkers and identify novel therapy targets, especially for ACC is of 
great interest54, 133, 134. 
 
 
1.4 Molecular basis of ACA and ACC 
 
In the last decades, a multitude of genetic abnormalities have been revealed in human 
cancer, some with diagnostic and prognostic implications. For ACT several genetic, 
genomic copy-number and molecular alterations have been reported57, 58, 128, 135, which 
have revealed differences between ACT and ACC54, 58, 81, 136-138. Many of these 
abnormalities have been associated to the malignant phenotype and poor prognosis 
such as the early presence of metastasis or local invasion in ACC (Table 1) 128, 139-141.  
 
Based on comparative genomic hybridization128, 142-144, the ACC genotype has been 
associated with multiple chromosomal gains and gene amplifications144, 145. Most 
commonly gains in ACC (at least 7 times more frequent than in ACA) have been 
observed in 5p, 5q, 12p, 12q, chromosome 19 and 4. Although similar alterations have 
also been detected in ACA, it seems that these gains are more prevalent in ACC. These 
genetic aberrations have been positively correlated to an increasing size of the 
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tumour144, 145. Based on these findings, the possibility of an ontogenetic progression in 
these tumours has been discussed144-147.  
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Many studies have consistently demonstrated that ACC specifically display an 
overexpression of the insulin-like growth factor 2 (IGF-2) and a constitutive activation 
of the beta-catenin as crucial events for the development of these tumours58.  
 
Mutations of the TP53 gene have been reported in some ACT cases. These have been 
strongly associated with a higher prevalence/predisposition of ACT in some specific 
populations. For example in a cohort in Southern Brazil a founder germline TP53 
mutation (R337H) was detected in 95% of childhood ACT148. This founder mutation 
has conditioned in this population an unusually higher incidence (4 times more) of 
ACC58. Nevertheless, as described for many cancers, it seems that these 
genetic/molecular changes are quite different in tumours between the paediatric and 
adult population138. For example in studies of adult cohorts, TP53 mutations have been 
established in approximately 25% of sporadic ACC144, 149-151.  
 
In 2011 recurrent mutations of the inwardly rectifying potassium channel gene 
(KCNJ5) were reported in approximately 36% of APA using a whole exome-capture 
plus Illumina sequencing approach152. Two recurrent mutations were identified 
which increase sodium conductance in the adrenal glomerulosa cells. This alteration 
in the channel selectivity induces aldosterone synthesis and cell proliferation. The 
finding has subsequently been reproduced in other populations153 also in a cohort 
from our own institution154.  
 
Very recently, hotspot mutations were also reported in the ATP1A1 and ATP2B3 
genes encoding an Na+/K+ ATPase alpha subunit and a Ca2+ ATPase, respectively155. 
These molecules are involved in sodium, potassium and calcium ion homeostasis. 
ATP1A1 and ATP2B3 were found mutated in 5.2% and 1.6% of APA. Patients with 
these somatic mutations showed autonomous aldosterone hypersecretion. 
 
 
1.5 Transcriptional studies in sporadic ACA and ACC 
 
The first step of gene expression is coding RNA or mRNA from a DNA template (a 
genetic process named transcription). This molecular process conduces regularly but 
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not always, to protein synthesis in a mechanism called translation. Gene expression 
has been associated to certain cellular features such as growth control, cellular death 
and differentiation. Therefore, it has been documented that in some pathological 
cellular states such as neoplasia certain gene expression levels could be changed or 
abnormally distorted, often showing a specific profile or pattern. In fact, cancer is 
usually considered as a heterogeneous group of diseases that all arise from discernible 
genetic changes. Changes at DNA or RNA level have been well documented in many 
cancers. Applied used of the whole or a subset of transcripts in medical genomics is 
frequently referred to as transcriptomics. The transcriptome constitute mainly of 
different forms of RNA, and it is directly related to the functional elements of the 
entire genome and may contribute to the better understanding of human disease156. 
Furthermore, mRNA expression profiling has unravelled some molecular markers 
between benign tumours and carcinoma, leading to novel diagnostic/prognostic tools 
such as the Mamma Print for breast and other cancers157-159. Moreover, this 
microarray-based diagnostic/prognostic tool has been demonstrated to be superior to 
its pathological counterpart, mainly for assessing the risk of metastases. Additionally, 
other molecular signature tools seem useful for improving the diagnostic classification 
among tumours, predominantly cancer and its subtypes160-163. These molecular 
signatures (specially a featured group of deregulated mRNA levels) have also proven to 
be reliable as predictors of malignancy, providing valuable independent information in 
addition to the clinical, biochemical and pathological assessment of cancer138, 164.  
 
Based on this appraisal, over-expression of some specific genes (Table 1) has been 
associated to certain ACT phenotypes such as CYP11A1 and HSD3B1 for CPA51, 165; 
CYP11B2 for APA166-170 and CYP21A2 for androgen secreting ACT170, 171.  Since 
many of these genes participate actively in steroidogenesis, it seems very probable that 
an abnormal expression of these genes may address the overproduction of specific 
steroid hormones in ACT and therefore a characteristic phenotype37, 46, 138, 166, 167, 169-172. 
These studies have contributed to a better understanding of the molecular pathogenesis 
of ACT and additionally to improve the diagnosis of certain clinical subtypes of 
hyperfunctioning ACT such as APA and CPA169, 171-173. However, due to the 
heterogeneous gene expression, its routine use for clinical diagnosis is still a matter of 
debate54, 173. In contrast, some specific genes have been related to ACC, such as IGF2 
and FGF1281, 138, 144, 145. In ACC, also other genes have been suggested to be 
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deregulated such as WNT, ALDH1A1, DLG7 and PINK181, 138, 149, 151, 174. In total, it 
seems that the malignant genetic signature is the more relevant, or useful, 
transcriptomic feature among ACT81, 138, 149.  A large part of the human transcriptome 
consists of non-coding RNAs. Recently, it was demonstrated that these RNAs play an 
important role in the regulation of gene expression175-177. MicroRNAs (miRNAs) 
represent a family of small non-coding RNA molecules and probably represent the 
largest proportion of regulatory RNAs. These molecules may affect the functional 
properties of almost 30% of the protein-coding genes176. Although the functional roles 
of many miRNA molecules are still unknown, they are involved in diverse 
physiological and pathological processes such as tissue development, cell 
differentiation, apoptosis, immune response and particularly tumourigenesis177-179. By 
microarray platforms it has been demonstrated that miRNA are differentially expressed 
between normal and some types of tumour tissues177, 180. However, the link between 
miRNA expression and tumourigenesis is still far from being completely understood.  
 
Moreover, few examples of the implication of these molecules in ACT have been 
reported181-183. Two separate groups184, 185 have demonstrated the up-regulation of miR-
483 in ACC as a potential biomarker. Additionally, the role of miRNA in the 
regulation of steroidogenesis in ACT has been documented, with a possible function 
on cell proliferation186. Although many of these studies have demonstrated the effect 
of some miRNA in steroidogenesis in ovarian granulosa cells187-189, most probably the 
effect of these miRNAs are similar in other steroidogenic tissues such as adrenal gland, 
placenta and brain. Among these miRNAs, miR-483, one of the most investigated 
miRNA in ACC, has been also associated to progesterone concentrations190. Other 
miRNAs such as miR-184, miR-195, miR-7, miR-503, miR-511 and miR-335 have also 
been documented as deregulated in ACC184, 185, 191-193.  Furthermore, in one study193, 
two miRNAs  (miR-503 and miR-511)  have been proposed as a tool for the 
differentiation of ACA and ACC tumours with 100% sensitivity and 93% specificity.  
On the other hand, miR-483 has demonstrated a 100% of positive predictive value and 
92% of negative predictive value for the ACC diagnosis191. Although these findings 
should be validated in larger cohorts, these results are promising for a better 
understanding of ACC development. 
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2 AIMS 
 
I. General Aims 
1. To explore by means of transcriptomic profiling (mRNA and miRNA) 
the differences between ACT regarding the malignant and benign 
phenotypes. 
2.  To explore by means of transcriptomic profiling (mRNA and miRNA) 
the differences between ACT regarding the hyperfunctioning and non-
hyperfunctioning phenotypes. 
 
II. Specific Aims 
1.  Paper I. - To determine if the expression profiling based on mRNA 
from ACT could provide for a distinction between ACA and ACC. 
2. Paper II. - To characterize mRNA expression profile in relation to the 
different subtypes of hormone producing and non-producing ACA. 
3. Paper III. -  To determine if the expression profiling based on miRNA 
from ACT could provide for a distinction between ACA and ACC. 
4. Paper IV. - To characterize miRNA expression profile in relation to the 
different subtypes of hormone producing and non-producing ACA. 
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3 MATERIAL AND METHODS 
 
3.1 Patients and Tumour Material 
 
This thesis is based on transcriptional analysis of snap-frozen adrenocortical tissues 
obtained from a cohort of patients diagnosed and managed at the Department of 
Surgery, Karolinska University Hospital. The cohort includes more than 300 patients 
operated at this medical institution from 1986 to 2011.  All included patients were 
biochemically screened and followed up for at least 1.5 years in their postoperative 
period. Every included sample was verified by histopathology according to the WHO 
classification194. A cellular representation equal or above 70% of tumour cells within 
each sample was required as an inclusion criterion. All APA cases included were 
confirmed with immunohistochemistry as described elsewhere96. Aldosterone-
secreting hyperplasia or non-solitary APAs were discarded. Diagnostic criteria for 
ACC were vascular invasion, invasion of surrounding tissues or structures and distant 
metastases. Sample sizes were variable across papers: 
 
Paper Normal Cortices Benign ACT ACC 
I 0 13 (5 ACA, 4 APA and 4 NHFA) 7 
II 4 17 (5 ACA, 4 APA and 8 NHFA) 11 
III 10 43 (13 ACA, 16 APA and 14 NHFA) 25 
IV 10 43 (13 ACA, 16 APA and 14 NHFA) 0 
Table 2. General description of the number of samples and their functional phenotypes 
included in the published papers considered for this thesis. 
 
 
General clinical and pathological features of the included cohort of patients/samples 
are included in the corresponding papers. For the miRNA inhibition and 
overexpression assays a commercially available cell line of ACC (NCI-H295R) from 
the American Type Culture Collection (ATCC# CRL-2128; LGC Standards, 
Middlesex, UK) was used. These cells were maintained in a DMEM:F12 medium, 
containing 2.5% of Nu-Serum serum replacements (BD Biosciences, Bedford, MA), 
1% of a mixture of penicillin and streptomycin and 1% sterile-filtered ITS+1 liquid 
media supplement (100X) at 37oC with a 5% of CO2. The ITS+1 liquid media (Sigma-
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Aldrich Logistik GmbH, Schnelldorf, Germany) contains 1.0 mg/ml of recombinant 
human insulin, 0.55 mg/ml of human transferrin and 0.5 µg/ml of sodium selenite. The 
authentication of this cell line was also evaluated and verified by Bio-Synthesis, Inc. 
(Lewisville, TX). For this purpose a genotyping of 15 short tandem repeat loci and the 
amelogenin gene (AMEL) were used. Comparisons were realized to the genotype 
information from the ATCC. 
 
3.2 Methods for mRNA studies 
 
3.2.1. mRNA isolation and purification 
Total RNA was isolated from mechanically homogenized adrenocortical frozen 
tissues (at least 30 mg of fresh or frozen tissue) by means of organic extraction 
using Trizol and purification by Qiagen Columns (RNeasy mini kits, 
www.qiagen.com) using standardised protocols195, 196.  This kit provides a fast 
purification of high-quality RNA from tissue human cells by means of a silica-
membrane included into spin columns with a binding capacity of at least 100 
micrograms of total RNA. Additionally, this kit allows an efficient purification of 
total RNA from relatively small amounts of starting material (0.5 mg of tissue). The 
method simplifies the RNA isolation combining the stringency of guanidine-
isothiocyanate lysis with the speed and purity of silica-membrane isolation.  Once 
samples are lysed with a commercial buffer (lysis buffer or RLT), 70% pure  
(molecular grade) ethanol is added to the lysate in order to provide an ideal binding 
condition. This lysate plus ethanol is then loaded onto the RNeasy spin columns and 
centrifuged by about 3 min at full speed in a microfuge. Supernatant was removed 
by pipetting and then transferred to a new micro centrifuge tube (Eppendorf tube). 
This lysate produces a RNA-silica binding in up to 100 micrograms capacity. 
Subsequently several washes are repeated in order to eliminate the contaminants 
and salts by means of commercial buffers (RW1 and RPE).  After this 
decontamination a technically pure RNA bind into the silica is eluted through the 
use of 30-100 microliters of RNase-free sterile water or TE buffer. A ND-1000 
spectrophotometer (Nanodrop, San Francisco, CA, USA) and a 2100 Bioanalyzer 
(Agilent technologies, Santa Clara, CA, USA) were used for assessing the quality 
and relative quantity of total RNA obtained in these extractions. A260/280 ratios 
from 1.7 to 2.1 are ideal for further applications of this total RNA. 
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3.2.2. Complementary DNA (cDNA) microarray 
Complementary DNA oligoarrays produced by KTH were used for mRNA 
expression profiling, following their general standard protocols (more details can be 
found at www.ktharray.se). These produced microarrays consisted of 29 760 cDNA 
fragments that were spotted onto an ultra GAPS slides (Corning, Corning, NY) with 
a QArray (Genetix, New Milton, UK).  These cDNA microarrays contained 
approximately 29 760 cDNA fragments representing 18 953 unique human 
UniGene IDs. Complementary DNA clones were taken from the sequence verified 
human clone collection, 97001.V (Research Genetics, Inc., Huntsville, AL, USA). 
Microarray was elaborated completely at the KTH by spotting onto Ultra GAPS 
crystal slides (Corning, Lowell, MA, USA) with a Qarray2 instrument with 48 
K2805 pins (Genetix, Hampshire, UK) in a 25 x 25 pattern within each of the 48 
blocks and with a feature centre-to-centre distance of 170 µm. The average size of 
the spots is approximately 110 µm. 
 
This array also includes 23 different controls with 8 copies of each one. Complete 
versions of these protocols are available at www.ktharray.se and at Array Express. 
Quality of spotted slides was assessed by Syto61 staining (Molecular probes, 
Eugene, OR, USA) and random nonamer hybridization. The slides were UV cross-
linked at 250 mJ/cm2 followed by baking at 75°C for 2 hours. A complete gene list 
can be found at www.biotech.kth.se/molbio/microarray. 
 
First strand cDNA target was generated by reverse transcription of 10 µg of total 
RNA in a 30 µl reaction using 10 µg anchored oligo dT primer (dT20VN, MWG 
Biotech AG), first-strand buffer (50 mM Tris-HCl, pH 8.3, 75 mM KCl, 3 mM 
MgCl2), 0.01 mM DTT, 400 units Superscript II (Invitrogen AB), 2 mM 
d(A/G/C)TPs, 1.6 mM dTTP (Amersham Biosciences) and 0.4 aminoallyl-dUTP 
(Sigma-Aldrich). Secondary structures of RNA and primers were removed at 70 °C 
during 10 minutes followed by 2 minutes of incubation on ice for primer annealing 
before addition of the other reaction components. Complementary DNA synthesis 
was performed during 2 hours at 42 °C. This reaction was terminated by addition of 
EDTA. The RNA was then hydrolysed in NaOH during 15 minutes incubation at 
70°C followed by neutralization with HCl (final concentrations 20 mM, 150 mM 
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and 150 mM, respectively). The cDNA was purified further using a MinElute spin 
columns (Qiagen GmbH) with the provided was buffer replaced by 80% ethanol 
molecular biology grade and the elution buffer by 100 mM NaHCO3, pH 9.0. 
Monofunctional NHS-ester Cy3 or Cy5 flurophores (Amersham Biosciences) were 
coupled to the amino-allyl groups during 30 minutes incubation at room 
temperature (22°C) after which the unincorporated ester groups were inactivated 
through the use of hydroxylamine (final concentration 730 mM). Tumour samples 
were labelled with Cy5 and Cy3 as reference. The labelling reactions were purified 
using MinElute spin columns. The complete protocol is available at 
www.biotech.kth.se/molbio/microarray/index.html. Extraction and labelling quality 
and quantity of the total RNA and cDNA were evaluated using a nanophotometer 
and an Agilent bioanalyzer 2100. 
  
Microarray slides were pre-hybridized in 5X SSC, 0.1% SDS and 1% bovine serum 
albumin (Sigma Aldrich) for 30 minutes at 42°C in a closed wet chamber. 
Hybridization buffer used for all these experiments were constituted with 25% 
formamide, 5X SSC, 0.1% SDS, 5X Dehardts, 20 µg poly (A) (Sigma Aldrich), 10 
µg COT-1 DNA (Invitrogen), 5 µg tRNA (Sigma-Aldrich). Hybridizations were 
carried out in hybridization closed wet chambers (Cat number 2551, Corning) for 
18 hours at 42 °C. Post-hybridization washing was necessary and carried out 
according to Corning's recommendations. All these hybridizations were performed 
in technical duplicates for decreasing the variance. All hybridizations were repeated 
at least twice (biological replicates) in an alternate way (benign and malign cases) 
for achieving an adequate statistical power.  
 
Arrays were scanned at 532 and 635 nm with 10µm resolution through the use of a 
G2565bBA DNA microarray scanner (Agilent Technologies). Image analysis was 
performed by means of GenePix 5.1 software (Axon instruments). Defective spots 
were considered whenever less than 70% of the foreground pixels were below the 
background intensity plus 2 standard deviations in both channels or if signal to 
noise ratio were below 3 in both channels or if the difference between ratio of all 
medians and regression ratio exceeded the 20% in one of the channels. After the 
removal of these defective spots the remaining intensities were print tip LOWESS 
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normalized within R environment for statistical computing with the aroma package 
(www.maths.lth.se/publications).  
 
Levels of gene expression were analysed in separate samples, tumour group (cluster 
of samples) and in comparison with the common RNA reference. Statistical 
analysis of these values (expressed as continuous dimensional data) was performed 
using the Aroma package for normalization and the LIMMA package for statistical 
testing of significance. Bayesian analysis and B-test for ranking on differentially 
expressed genes was also performed on the average of technical replicates on genes 
represented in all samples. This was performed using the Limma package. 
Clustering was performed with the stats and class packages (www.R-project.org). 
Unsupervised hierarchical clustering of all included genes for visualization of 
expression patterns was performed in MeV (www.tigr.org). Functional gene 
annotation was determined based on Gene Ontology 
(www.geneontology.org/GO.doc.html). Fisher's exact test or square chi test were 
used to evaluate the significant over-representation of GO terms and chromosomal 
location for differentially expressed genes among samples. 
 
 
3.2.3. Validation by quantitative RT-PCR (qRT-PCR) 
In order to validate the array findings for differentially expressed genes validation 
with quantitative real time polymerase chain reaction (qRT-PCR) was performed. A 
two-step TaqMan qRT-PCR was used for testing genes such as ALDH1A1 (hs 
00167445_m1), IGF2 (hs 00171254_m1) USP4 (hs 00234300_m1) and UFD1L (hs 
00799945_s1). Synthesis of cDNA from total RNA was obtained using the high-
capacity cDNA archive kit (Applied Biosystems). Approximately 0.5 to 1 µg of 
RNA was used from every included sample. An enzyme cocktail was added 
containing 10X reverse transcription buffer, 25X dNTP, 10X random primers, 
nuclease-free water and a MultiScribe reverse transcriptase (50 U/µl) in a final total 
volume of 50 µl. This reaction was load into 96-well plates into a GeneAMp PCR 
System 9700 thermal cycler (Applied Biosystems). The following conditions were 
used for the RTPCR: an initial hold phase of 25 °C for 10 minutes for incubation, 2 
hold phases with 37°C for 60 minutes for reverse transcription, a fourth phase with 
37°C for 7 minutes and a final phase with 4°C for 30 seconds. The plate was 
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immediately removed after completing cycling and store at -15 to 25°C for later 
reading and use. A 96-well plate was prepared also for the TaqMan gene expression 
assays (Applied Biosystems). This is a 5 prime fluorogenic nuclease assay, which 
quantifies the relative abundance of specific RNA transcripts. Every well 
approximately contained 12.5 µl of TaqMan universal master mix with 1.25 µl of 
primers plus probmix (Assays on Demand from Applied Biosystems), 6.25 µl of 
RNase-free water and 5 µl of cDNA or previously prepared dilutions (for the 
reference curve). Dilutions were prepared for 1:10, 1:100, and 1:10 000. Every 
sample and control well was done in triplicates and the housekeeping genes in 
duplicates according to manufacturer's recommendations. A non-template control 
(NTC) was included in every run. Plates were sealed with microAmp optical caps 
for avoiding leakage. A brief centrifugation (a couple of minutes) was done to spin 
down the contents and eliminate any air bubbles from the solutions contained in 
very well within the plate. Plates were then loaded into the ABI PRISM 7700 
sequence detection system (Applied Biosystems). In order to select a housekeeping 
gene as a reference for the relative quantification, the TaqMan human endogenous 
control plate was used. With this plate, the expression of 11 selected housekeeping 
genes was evaluated, using a two-step RTPCR. The plate also features a unique 
internal positive control (IPC) designed to detect the presence of PCR inhibitor 
among test samples. Analysis of the following housekeeping genes was performed: 
an internal positive control, 18S rRNA, acidic ribosomal protein, beta-actin, 
cyclophilin, glyceraldehydes-3phosphate dehydrogenase, phosphoglycerokinase, 
beta2-microglobulin, beta-glucoronidase, hypoxanthine ribosyl transferase, 
transcription factor IID, TATA binding protein and the transferrin receptor. 
 
 
3.3 Western blot analysis 
 
For the mRNA based studies, fresh frozen tissue samples were initially grounded 
into powder by mortaring on dry ice and subsequently dissolved by sonication in a 
buffer containing 50 mM Tris (pH 7.4), 5 mM MgCl2, 250 mM sucrose, 1 mM 
DTT and 1 mM ATP. Total protein extractions were then clarified by centrifugation 
and the lysates were snap frozen in liquid nitrogen. These aliquots were preserved 
in ultra-freezer until further use. For the Western blot analysis approximately 20 µg 
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of the protein aliquot preserved previously was used. This sample was fractionated 
on SDS-PAGE 4-12% gradient gels (Novex©, Invitrogen, Life Technologies), and 
blotted on PVDF membranes, blocked in a PBS buffer supplemented with 5% skim 
milk and 0.1% Tween® detergent. Then an aliquot of this sample was probed with 
an anti-Usp4 antibody (C-terminal; Abgent Inc., San Diego, CA, USA) with a 
dilution of 1:500.  Several buffer washings was followed by incubation with HRP-
conjugated goat anti-rabbit serum (Amersham Biosciences). A positive control for 
the Usp4 antibody was transfected human embryonic kidney 293T cells with a 
plasmid expressing USP4 in fusion with green fluorescent protein and harvested 
these cells for western blot analysis after 2 days of transfection. All protein blots 
were developed by enhanced chemiluminescence method (ECLTM Western Blotting 
Detection System; GE Healthcare (Uppsala, Sweden). Solutions for the 
development were equilibrated to at room temperature and mixed in equal volumes 
directly before their use. Fast exposure to film was required for optimal signal 
detection.  
 
For the microRNA (miRNA) based studies, total proteins were extracted from 
whole cell lysates obtained from adrenal references and ACT samples through 
homogenization within a NP40 Cell Lysis buffer (Invitrogen, Life Technologies), 
with the previous addition of a protease inhibitor mix (Complete protease inhibitor 
cocktail; Roche Diagnostics Corporation, Indianapolis, IN) and 1 mM of 
phenylmethanesulfonyl fluoride (Sigma-Aldrich). Protein quantification was 
performed by a colorimetric assay (Bio-Rad Protein Assay Kit; Bio-Rad© 
Laboratories). Approximately 60 µg of the lysate was separated using the Novex® 
10% Tricine gels (Invitrogen, Life Technologies, Carlsbad, CA) and transferred 
into nitrocellulose membranes (Invitrogen). The Novex® Tricine gel system is a 
modification of the Tris-glycine gel system and allows a better resolution of the low 
molecular weight proteins. Filters were blocked with 5% skim milk diluted in TBS 
buffer with 0.1% Tween 20 Then they were incubated with anti-PUMA antibodies 
(Cell Signalling Technology) at a 1:1000 dilution, followed by an anti-rabbit IgG-
HRP at a 1:3000 dilution (Bio-Rad© Laboratories, Hercules, CA) used as secondary 
antibody. Subsequent incubation of the filters with a GAPDH antibody (Santa Cruz 
Biotechnology Inc.) diluted at 1:5000 was performed for normalization purposes as 
a control. Blot detection was carried out with Novex ECL HRP chemiluminescent 
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substrate reagent (Invitrogen). The Novex Sharp Pre-stained protein standards 
(Invitrogen) and a Magic Mark™ XP (Invitrogen) western blot protein standard 
were used.  This standard allows the direct visualization of different protein 
standard bands on a blot without the need for protein modification or special 
detection reagents. The range of this standard is from 20 to 200 kDa proteins. The 
protein levels were quantified on X-ray films from immunoblots using the Image J 
software (http://rsb.info.nih.gov/ij/).  
 
 
3.4 Methods for microRNA (miRNA) based studies 
 
3.4.1. MiRNA isolation and purification 
For studies of miRNA expression, experimental and analysis procedures previously 
established in our group were used197. Total RNA was isolated using standard 
mirVanaTM miRNA isolation kit (by Ambion) following the protocol recommended 
by the manufacturer. This kit utilises a combination of an organic with a solid-phase 
extraction of RNA with high yield, ultra-purity and high quality results. Fresh or 
frozen tissue samples were slightly unfrozen and mechanically homogenized.  At 
least 30 mg of adrenocortical tissue (either normal or pathological) were used in 
every extraction. A representative tumour cell population was assessed by 
histopathology every time RNA or DNA was extracted and purified. Tumour tissue 
homogenization was performed with the fragment immersed in denaturing lysis 
buffer. Before any extraction was done, the bench, pipettors and all surfaces were 
cleaned with RNaseZap© Solution (Ambion, Life Technologies) and 70% ethanol 
for decontaminating RNase or other contaminating molecules by simply spraying 
and wiping.  
 
After disrupting the sample, this was subjected to acid-phenol chloroform extraction 
for improving the purification of the RNA and cleansing off the genomic DNA.  
For this, several aliquots were obtained with approximately 10 volumes per tissue 
mass of lysis-binding buffer into the homogenization tube (included in the kit). 
During all the disruption process, the tubes were kept submerged on crushed ice for 
keeping the sample cold. Disruption was continued until no clumps or tissue 
fragments were visible. The mixture was transferred to a new and sterile Eppendorf 
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tube and added 1/10 volume of miRNA homogenate additive (included in the kit) 
mixing well by vortexing by approximately 2-3 minutes. The sample was left on ice 
for 10 minutes and then the acid-phenol chloroform was added in an equal volume 
to the total lysate volume obtained in previous phases. Samples were vortexed for 
30 to 60 seconds in order to homogenize the contents and then centrifuged for 5 
minutes at maximum speed (10 000 x g) at room temperature. After centrifugation 
two phases were required to be noted: aqueous and organic phases, in the case these 
were not clear, the centrifugation was repeated. The upper aqueous phase was 
carefully removed with a pipette without disturbing the lower organic phase for 
avoiding contamination. Aqueous phase was then transferred to a new sterile 
Eppendorf tube and the organic phase was discarded. Then 100% ethanol 
(molecular grade and at room temperature) was added 1/3 volume to the aqueous 
phase recovered from the organic extraction. Sample was mixed thoroughly by 
vortexing for a couple of minutes. This lysate plus ethanol mixture was pipetted 
onto the filter cartridge (included also in the kit) up to 500 µl. The tube was 
centrifuged at 10 000 rpm for approximately 15 seconds in order to pass the mixture 
through the filter. The filtrate was collected and room temperature 100% ethanol 
(molecular grade) was added 2/3-volume. This mixture was pipetted and applied to 
the filter cartridge. This was centrifuged at 10 000 rpm for approximately 15 
seconds. The flow-through was discarded and applied 500 µl of miRNA wash 
solution 1 to the filter cartridge and centrifuged for approximately 10 seconds. 
Approximately 500 µl of wash solution 2/3 was applied two times and repeated the 
centrifugation. After discarding the flow-through from the washes, the filter 
cartridge was transferred into a fresh collection Eppendorf tube and applied 100 µl 
of pre-heated (at 95 °C) elution solution to the centre of the filter carefully with the 
pipette and close the cap. Sample was centrifuged at 10 000 rpm for approximately 
20-30 seconds in order to recover the enriched RNA. Samples were stored at least 
at -20°C until their use in further steps. 
 
RNA was always assessed through the use of a spectrophotometer. A ND-1000 
spectrophotometer (Nanodrop, San Francisco, CA, USA) was used for assessing the 
quality and relative quantity of total RNA obtained in these extractions. A260/280 
ratios from 1.7 to 2.1 are ideal for further applications of this total RNA.  
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3.4.2. MiRNA global profiling microarray 
Subsequently, samples were labelled with Cyanine 3-pCp and hybridized at 55°C 
for 22 hours to previously prepared Agilent oligoarrays for miRNA global profiling 
following a standardized protocol. This microarray contained 903 human miRNA 
obtained from the Mir Base release 14. After a washing phase, the arrays were 
scanned immediately into an Agilent scanner G2565BA.  Processing of images was 
done using Feature Extraction Software v10.7.3.1 (Agilent). Through the use of 
Cluster 3.0, raw data was normalized and centred the raw data based on medians. 
Once miRNA were normalised, miRNA with a limited proportion (for example 
<50%) of missing calls were included in subsequent statistical comparisons 
between ACT subgroups (functioning or malignant phenotype). Significance 
Analysis of Microarrays (SAM) included in the multi-experiment viewer software 
(TM4 MeV version 4.8) was used for contrasting phenotypes. In order to reach 
adequate stringency for the statistical inference, a false discovery rate equal or less 
than 5% or 0.05 was set up.  
 
3.4.3. Validation by quantitative RT-PCR (qRT-PCR) 
Finally selected miRNA were subsequently further validated using commercially 
available TaqMan® (Applied Biosystems) qRT-PCR microRNA Assays 
(www.appliedbiosystems.com). All 43 ACAs and 10 adrenal references were 
included for this qRT-PCR validation. The expression levels of 14 selected mature 
miRNAs were measured: miR-21 (ID 000397), miR-186 (ID 002105), miR-497 (ID 
001043), miR-210 (ID 000512), miR-10b (ID 002218), miR-320b (ID 002844), 
miR-320c (ID 241053_mat), miR-30e (ID 000422), let-7f (ID 000382), miR-139-5p 
(ID 002289), miR-195 (ID 000494), miR-1274b (ID 002884), miR-34a (ID 000426) 
and miR-520d-3p (ID 002743).  
 
The levels of the expression of 4 miRNAs (miR-21, miR-210, miR-195 and miR-
497) were also quantified and compared across the same ACT samples in paper III. 
RNU6B (ID 001093) was used as an endogenous control for normalization of the 
miRNA expression level. The relative expression quantification was performed by 
the ∆CT method and calculated as 2-∆CT. All reactions were run in triplicates. 
Statistical analysis was performed through the use of IBM® SPSS® Statistics 
software version 20.0 (IBM Corp., Chicago, IL) and Excel 2011of Microsoft 
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Office. Unpaired Student t-test for independent samples and one-way ANOVA 
were performed to compare differences in miRNA expression levels between 
studied groups. Other variables were analysed according to their scaling using chi-
square test for categorical variables and t-test for dimensional variables. All 
hypotheses were two-sided tests, considering any p value ≤0.05 or 5% as 
statistically significant. 
 
 
3.4.4. MiRNA inhibition and overexpression assays 
For this purpose a commercial line of ACC cells (NCI-H295R) was used. These 
cells were transfected using the Amaxa Nucleofector® technology (Amaxa 
Biosystems, Gaithersburg, MD). This is a commercially available and highly 
efficient non-viral transfection method. Approximately 3x106 cells were suspended 
in 100 µl of the Nucleofector solution and mixed with 100 picomoles of miRNA 
inhibitors (anti-miR-483-3p or anti-miR-483-5p; Applied Biosystems/Ambion) or 
miRNA precursors (pre-miR-195 or pre-miR-497; Applied Biosystems/Ambion). 
An anti-miR negative control#1 or pre-miR Negative control#1 (Applied 
Biosystems/Ambion) containing a non-targeting sequence molecule were used as a 
negative control. Cells were then electroporated using the program T-20, allowed to 
recover in DMEM: F12 cell culture media for 15 min at 37°C and seeded in T-25 
flasks with 5 ml DMEM: F12 cell culture media.  Culture media was replaced after 
24 hours and cells were cultured for additional 72 hours. The transfection efficiency 
was determined by measuring the endogenous miR-483-3p, miR-483-5p, miR-195 
or miR-497 expression levels by qRT-PCR. All transfection experiments were 
performed in triplicates. 
 
3.4.5. Cell proliferation assay 
A colorimetric assay using the cell proliferation reagent WST-1 (Roche Applied 
Science, Mannheim, Germany) was used in order to determine the inhibitory or 
proliferative effects of some miRNA on cell proliferation. This assay allows the 
non-radioactive, spectrophotometric quantification of cell proliferation and growth 
of cell lines. The proliferative effect of miR-483-3p and miR-483-5p and the 
inhibitory effect of miR-195 and miR-497 on cell lines were separately assessed. 
This assay was performed using 96-well plates, with approximately 20 000 cells 
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containing in each well. After 72 hours of transfection, 20 µl of the WST-1 solution 
were added to the culture medium and incubated for 2.5 hours at 37°C. The 
absorbance was subsequently determined using a VersaMax™ microplate reader 
(Molecular Devices, Sunnyvale, CA). All raw data were further collected and 
analysed with SoftMax® Pro Version 5 software (Molecular Devices) applying the 
wavelengths 450 nm for measurements and 650 nm as reference. All experiments 
were conducted in 8 wells for each condition, and replicated at least three times. 
Cell proliferation was calculated by comparing the absorbance values between the 
samples after background subtraction. The fraction of surviving cells was calculated 
by defining the anti-miR (or pre-miR)-Negative control #1-treated cells as 1.  
 
The WST-1 cell viability assay measures the metabolic activity in cell populations 
such as the MTT and the XTT methods. The WST-1 solution is added to the cells 
cultured, followed by incubation. During the incubation lapse, the WST-1 is 
converted into a coloured, soluble formazan salt (a water-insoluble coloured azo 
compound formed by reduction of a tretazolium salt) by the metabolic activity of 
viable cells. Then, the quantity of formazan obtained is quantified by an ELISA 
method by a microplate reader at 420-480 nm. This method does not require a cell 
transfer, is entirely performed in a single microplate with a ready-to-use solution. 
The main limitation of the WST-1 assay is that this method is not lineal over a 
broad logarithmic cell proliferation range due to the ELISA plate reader. 
 
3.4.6. Apoptosis assay 
The Caspase-3 colorimetric assay kit (Genscript, Piscataway, NJ) was used to 
evaluate the effects of miR-483-3p and miR-483-5p inhibition or miR-195 and miR-
497 overexpression on cell apoptosis. This method allows the activity of caspase-3 
through the spectrophotometric detection of the chromophore pnitroanilide (pNA) 
after its cleavage from the labelled substrate DEVD-pNA. The pNA is quantified in 
a microtiter plate at 400 or 405 nm. Comparing the measured absorbance of pNA 
between an apoptotic sample or non-apoptotic control the apoptotic (caspase-3) 
activity is relatively quantified. This kit includes 15 ml of lysis buffer, 5 ml of a 2X 
reaction buffer, 500 µl of a caspase-3 substrate and 150 µl of DTT. 
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The assay was performed with approximately 3x106 cells into T-25 flasks. After 72 
hours of transfection, proteins were isolated and quantified by Bio-Rad© Protein 
Assay (Bio-Rad© Laboratories). About 50 µl of lysate containing 50 µg of protein 
was mixed with 50 µl of 2X Reaction Buffer and 5 µl of caspase-3 substrate. This 
mixture was then incubated at 37°C for 4 hours. The absorbance was subsequently 
determined using a VersaMax™ microplate reader (Molecular Devices, Sunnyvale, 
CA) and analysed also with SoftMax® Pro Version 5 software (Molecular Devices) 
applying the wavelengths 405 nm for measurement. Apoptosis was calculated by 
comparing the absorbance values of the anti-miR/ pre-miR treated cells with the 
respective negative control treated cells. All the experiments were performed in 
triplicates.  
 
 
3.5 Statistical Methods 
 
In general terms, mRNA and miRNA expression levels are referred to as a 
quantitative dimensional scale (represented as mean ± standard deviation), even 
though medians may be used for normalisation. Proper statistical tests for 
contrasting two or more means are the unpaired t-test for independent samples, 
ANOVA and the non-parametric version of this: the Kruskal-Wallis test. In an 
experiment of multiple hypotheses testing, an adjustment for the regular p value is 
compulsory. Transcriptomic profiles include hundreds or thousands of 
mRNA/miRNA expression levels at the same time.  Significance analysis of 
microarrays (SAM) is a statistical technique developed for discerning differentially 
expressed genes among samples198, 199. This allowed the possibility for contrasting 
many hundreds or thousands mRNA/miRNA by multiple t-tests, measuring the 
strength of the relationship between mRNA/miRNA expression and the contrasting 
phenotypes (regarding functionality or malignancy). Repeated permutations are 
frequently used in this technique in order to investigate the different 
mRNA/miRNA combinations regarding the phenotypes. The use of this method 
allows looking for correlations among mRNA/miRNA avoiding parametric 
assumptions (such as a Gaussian distribution) of separate mRNA or miRNA. SAM 
uses a false discovery rate (FDR) and fold change for establishing differences 
between mRNA/miRNA expression levels regarding the tumour phenotype. Once a 
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FDR cut-off value is set up, a list of significant or differentially expressed 
mRNA/miRNA can be applied. All statistical analysis was performed through the 
use of IBM® SPSS® Statistics software version 20.0 (IBM Corp., Chicago, IL) and 
Excel 2011of Microsoft Office, this last mainly for data representation and 
graphics. Linear correlation was also used by means of Pearson or Spearman tests. 
Other variables were analysed according to their scaling using chi-square test for 
categorical variables and t-test for dimensional variables. Any p value equal or less 
than 0.5 or 5% was considered significant for a two-tied hypothesis testing. 
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4 RESULTS AND DISCUSSION 
 
4.1 mRNA Expression Profiles of ACC and ACA (Paper I). - 
Expression profiling of adrenocortical tumours suggests a molecular signature of 
malignancy. The spotted cDNA oligo-array aforementioned by competitive 
hybridization was used in this study. This microarray was made and processed at the 
KTH which explored more than 25 000 cDNA fragments obtained from a verified and 
sequenced human clone collection (97001 V). In this very first approach, 
transcriptomic expression profiles between 7 ACC and 13 ACT were compared. 
Several issues were taken into account, such as histopathological representative 
proportion of tumour cells, hybridization duplicates and sufficient clinical follow-up in 
all patients.  
 
Transcriptional profiling among the benign ACTs was more homogenous than among 
ACCs. Moreover, a set of stochastic expression levels for genes made it possible to 
categorise benign ACT from ACC clearly (Figure 1 in paper 1). In this heat map 
dendogram, the genes were clustered with the use of Euclidean distances and average 
linkage to provide an overview of the general pattern. The expression profiles of 
adenomas were observed homogenous while the ACC profile was heterogeneous. 
When clustering these samples, adenomas and ACC were clustered separately.  
 
Additionally, several genes were significantly up regulated in ACC such as USP4, 
IFD1L and IGF2. Interestingly, several genes related to the IGF family were up 
regulated such as IGF2, IGF2R, IGFBP3 and IGFBP6.  This group of genes were 
good candidates for a better clinical classification between ACC and benign ACT 
(Figure 2 in Paper 1).  
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Moreover, many of the 571 deregulated genes found in ACC were functionally 
localized in the nucleus according to GO tools. Chromosomal location was also 
performed through the use of Locus Link. With this tool a significant over-
representation in chromosomes 5 and 12 were determined for up regulated genes 
mainly in ACC.  
 
 
Figure 9. Histograms representing the differentially expressed levels of 
IGF-related transcripts between benign ACT and ACC. 
 
Our results at this point showed that the transcriptomic profile was different between 
ACC and ACA. Some specific mRNA such as USP4 showed to be up regulated at 
least 40 times more in ACC than ACA. An important group of these up regulated 
genes included members of the IGF family. One of these, IGF2 was the most 
consistently found up regulated in ACC. It seemed evident that through the use of 
transcriptomic profiling ACA can be confidently discerned from ACC. Additionally, a 
molecular signature was feasible to construct.  
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In conclusion, this first paper showed the main differences between ACC and benign 
ACT at their intrinsic transcriptomic level. The transcriptional profiling allowed the 
discrimination of ACC from other ACT, even from a limited amount (the 50 most 
significantly) of differentially expressed genes. Despite the fact that cDNA arrays may 
be expensive, a simple qRT-PCR of a molecular signature composed by a limited 
amount of genes is not only feasible but also germane into the clinical scenario. 
Figure 10. Heat maps representing the expression profiles of the 50 top 
most up- (red) and down-regulated (green) genes between ACA and 
ACC. 
 
  41 
4.2 mRNA Expression Profiles of ACT Subgroups (Paper II). -  
Transcriptional profiling enables molecular classification of adrenocortical 
tumours. The primary aim of this study was to better classify ACC and ACT based on 
their hyperfunctioning phenotype and to explore mRNA expression’s implication on 
survival. Using the same technology (transcriptomic-based microarrays) the 
transcriptional profile of 17 ACA, 11 ACC and 4 normal adrenal cortices were 
determined. Findings were validated by RT-PCR and western blot analysis.  A 
molecular signature comprising 50 genes was sufficient for dichotomising ACC from 
benign ACT and normal adrenal cortices (Figure 2 in paper II).  
 
The discrepancy based on the transcriptomic profiled between ACC was once again 
striking; moreover subgroups within the ACA phenotype were noted. NHFA, APA 
and CPA clustered separately, even though normal references clustered with CPA.  
Some differentially expressed (DE) genes such as VEGFB and OSBP were related 
exclusively to APA and not with CPA, normal references or NHFA.  
 
Two groups of genes especially up regulated in ACC were further validated; growth 
factor signalling and ubiquitin-proteasome pathway related genes. Furthermore, two 
subgroups of ACC with different survival outcomes based on their transcriptional 
profiles could be discriminated. Certain specific genes were up regulated in some 
specific phenotypes among ACT, such as OSBP and VEGFB in APA.  
 
Additionally, principal component analysis and unsupervised clustering of expression 
profiles made it possible to discriminate between benign and malignant phenotypes in 
ACT (Figure 1 in Paper II). Normal references clustered together, in a similar manner 
as other ACTs. The normal cases clustered with benign adenomas, mainly CPAs or 
NHFAs.  
 
In addition, two subgroups of ACCs were determined based on their transcriptomic 
profile. These subgroups behaved differently regarding their clinical survival: a short-
survival group (equal or less than 9 months) and another with long-survival (more than 
67 months). This fact conducted the hypothesis that this transcriptomic profile (Figure 
5A in paper II) might be used for prognostic purposes among these patients (Figure 5B 
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in paper II). Currently, there are very limited features related to ACC, which are able 
to have a predictive value on the survival time in these patients. 
 
 
Figure 11. Heat maps representing the expression profiles of the most 
up- (red) and down-regulated (green) genes between two subsets of 
ACC. 
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In conclusion, paper II focused on the hyperfunctioning phenotype and prognostic 
discrimination in ACA and ACC respectively. This goal was achieved by the use of 
the transcriptomic profile and some specific genes such as OSBP and VEGFB for 
APA.  
 
 
 
 
Interestingly, two subgroups of ACC with different survival times were also identified 
based on this profile. Although microarrays may be expensive and impractical for 
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everyday clinical use, a PCR based assay using a limited number of genes could prove 
to be a useful prognostic tool in ACC patients.  
 
 
Figure 13. Kaplan-Meier survival curve showing the longer survival 
observed for cluster 1 of ACC regarding cluster 2 of ACC. 
 
 
4.3 miRNA Expression Profiles of ACC and ACA (Paper III). -  
The role of miRNA deregulation in the pathogenesis of ACC. Contrasting the two 
previous papers, miRNA expression profiling as an organization tool for 
discriminating ACC from ACA was used. In addition, the predictive value of miRNA 
expression regarding the clinical prognosis of ACC patients was evaluated.   
Transcriptomic profiles based on miRNA expression levels were quantified in a series 
of 68 ACTs (13 ACA, 16 APA, 14 NHFA and 25 ACC) and 10 normal reference 
adrenal cortices. 
 
The transcriptomic profile made it possible to discriminate benign ACT from ACC.  
The signature for this classification included 72 deregulated miRNA such as miR-483-
3p, miR-210, miR-21, miR-1974 and miR-195 among others.  When survival was used 
as an outcome, three clusters within the ACC group were revealed by SAM analysis. 
Signature associated to differential survival included 9 miRNA (miR-503, miR-379, 
miR-1915, miR-381, miR-638, miR-886-3p, miR-671-5p, miR-23a, and miR-27a). 
  45 
Relative high levels of expression of the first seven and low expression of the last two 
were associated with a shorter survival in patients with ACC (Figure 5 Paper III).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Cumulative survival plots for cluster 1 and 2 of ACC based 
on differentially expressed miRNA profiles. 
 
 
The transcriptomic profile, this time based on miRNA, was again capable of 
discriminating ACC from ACA. For a second time, the consistency of these findings 
was supported by qRT-PCR validation. Moreover, cell proliferation and apoptotic 
assays were used in this paper in order to elucidate the functional role of some DE 
miRNA. This was the case of miR-483-3p, which showed a proliferative, but not 
apoptotic effect in NCI-H295R cells. Interestingly, this miRNA has been located 
within the second intron of the IGF2 locus200. This study reported that miR-483-3p and 
IGF2 might cooperate or even act independently as oncogenes. Hence, demonstrating 
two transcripts with a strong value for discriminating between ACC from ACA was 
very interesting.  
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4.4 miRNA Expression Profiles of ACA Subgroups (Paper IV). -  
MiRNA expression patterns allow categorisation between hyperfunctioning and 
non-hyperfunctioning phenotypes in adrenocortical adenomas. 
Distinctive miRNA profiles regarding the functional phenotype among ACTs were 
analysed and characterized. Using the same transcriptomic platform and 68 ACT as in 
Paper III, the hypothesis that these may discriminate the functional phenotype was 
tested. Clustering based on this transcriptomic tool allowed the discrimination between 
the three most common ACT phenotypes: CPA, APA and NHFA. Altogether, NHFA 
classified within either of the hyperfunctioning phenotypes (CPA or APA). When 
NHFA was discarded, CPA and APA classified separately (Fig 1a and 1B paper IV).  
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Interestingly, most of the deregulated miRNAs were up regulated in hyperfunctioning 
phenotypes. Moreover, at least 10 miRNAs were differentially expressed in ACA 
when compared to normal cortices. Some of these differentially expressed miRNA 
were “private” or uniquely deregulated in functional ACT such as APA. Additionally, 
two APA clusters were observed, although the presence of KCNJ5 mutation was not 
decisive for the clustering of these two subgroups. 
 
As conclusion in this paper, transcriptional profiling based on miRNA may also 
contribute to a better phenotype classification of ACT regarding their hormonal over 
secretion. The reiterated finding that the transcriptome is categorical between ACA 
and ACC might elucidate stochastic differences at the biological and cellular level of 
ACT. In addition, it seems that some oncogenes may have an important role in ACC as 
well as in ACA. For example miR-21 has been demonstrated to harbour dual functions 
such as promoting cell proliferation and steroidogenesis among hyperfunctioning 
phenotypes. Differences at the transcriptomic level are not only a reflection of the 
prevailing cell functional capacities but also of its future comportment. 
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5 CONCLUDING REMARKS 
 
The primary general aim was to characterize the transcriptional patterns for mRNA 
and miRNA among ACTs, especially regarding the malignant phenotype. In papers I 
and III it was possible to correctly classify the ACTs into two different phenotypes: 
malignant (ACC) or benign tumours (ACA). Throughout these studies, these profiles 
were discrete and categorical between ACC and benign ACT phenotypes, although the 
transcriptomic pattern in ACC showed to be somewhat heterogeneous. Additionally, 
some of these transcriptional elements showed a predictive value associated with 
survival in patients with ACC. In paper II, mRNA expression patterns were able to 
identify two groups of ACC with contrasting survival times, whereas in paper III some 
specific miRNAs lead to the identification of ACC subgroups with varying prognosis.  
 
The secondary general aim was accomplished in paper II and IV by demonstrating that 
it is possible to discriminate between the hyperfunctioning ACAs (especially APA and 
CPA) through the use of transcriptomic profiling. Additionally, NHFA clustered in 
either APA or CPA nearly indistinctly but differently from normal cortices and ACC. 
As expected, particular transcript signatures between functioning/non-functioning 
phenotypes, elucidating some of the molecular mechanisms involved in these 
phenotypes. Certain mRNA (such as OSBP and VEGFB) and miRNA (such as miR-
130a and miR-185) were “private” or uniquely deregulated in APA.  
 
It is hereby documented that the transcriptional profiling is a useful tool for 
distinguishing specific phenotypes with clinical interest such as malignant or 
hyperfunctioning ACTs. Additionally, this knowledge could contribute to a better 
understanding of the molecular mechanisms underlying the development of these 
tumours. 
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Carlo, Beatriz, Mariana y Familia Dagnino Frisbie gracias por su linda amistad. 
Mil gracias Juan Pablo Pantoja: mentor, colega y amigo.. que más le puedo pedir a 
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Muchas gracias Mauricio Sierra, gracias por tus sabios consejos! gracias por ser 
amigo. 
Rosario Reyes: gracias chaparra de mi alma! No sólo has sido una madre, sino una 
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David Monterrubio, Blanca, David Jr. y Fer. Gracias por dejarme ser parte de su 
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Gabriela Mercado:  Mi amiga del alma. Gracias por todo el cariño y apoyo de 
siempre! 
Alejandra Contreras y Abel: Muchísimas gracias por su cariño y apoyo siempre!   
 
In the case I have forgotten someone, please receive my apologies but honest thanks 
from the bottom of my heart.  Thanks all for sharing my lifetime, challenging my 
mind, touch my soul, warm my heart and resist my temper. 
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